Andrej Wagner1, Ulrike W Denzer2,3, Daniel Neureiter4, Tobias Kiesslich1,5, Andreas Puespoeck6,7, Erik A J Rauws8, Klaus Emmanuel9, Nora Degenhardt2, Ulrich Frick10, Ulrich Beuers8, Ansgar W Lohse2, Frieder Berr1, Gernot W Wolkersdörfer1. 1. Department of Medicine I, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Salzburg, Austria. 2. Department of Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Clinic for Interdisciplinary Endoscopy, University Hospital, Hamburg-Eppendorf, Hamburg, Germany. 4. Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Salzburg, Austria. 5. Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria. 6. Department of Internal Medicine IV, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. 7. Department of Internal Medicine II, Krankenhaus der Barmherzigen Brueder, Eisenstadt, Austria. 8. Academic Medical Centre, Department of Gastroenterology & Hepatology, Amsterdam, The Netherlands. 9. Department of General and Visceral Surgery, Krankenhaus Barmherzige Schwestern Linz, Austria. 10. Doepfer University of Applied Sciences, Cologne, Germany.
Abstract
UNLABELLED: Photodynamic therapy using porfimer (P-PDT) improves palliation and survival in nonresectable hilar bile duct cancer. Tumoricidal penetration depth of temoporfin-PDT (T-PDT) is twice that of P-PDT. In a single-arm phase II study we investigated the safety, efficacy, survival time, and adverse events of T-PDT compared with previous data on P-PDT. Twenty-nine patients (median 71 [range 47-88] years) with nonresectable hilar bile duct cancer were treated with T-PDT (median 1 [range 1-4] sessions) plus stenting and followed up every 3 months. The PDT was well tolerated. In patients with occluded segments at baseline (n=28) a reopening of a median of 3 (range 1-7) segments could be achieved: n=16 local response and n=11 stable local disease, one progressive disease. Cholestasis and performance significantly improved when impaired at baseline. Time to local tumor progression was a median of 6.5 (2.7-41.0) months. Overall survival time was a median of 15.4 (range 4.4-62.4) months. Patients died from tumor progression (55%), cholangitis (18%), pneumonia (7%), hemobilia (7%), esophagus variceal hemorrhage (3%), and vascular diseases (10%). Adverse events were cholangitis (n=4), liver abscess (n=2), cholecystitis (n=2), phototoxic skin (n=5), and injection site reactions (n=7). Compared to previous P-PDT, T-PDT shows prolonged time to local tumor progression (median 6.5 versus 4.3 months, P<0.01), fewer PDT treatments needed (median 1 versus 3, P<0.01), a higher 6-month survival rate (83% versus 70%, P<0.01), and a trend for longer overall median survival (15.4 versus 9.3 months, P=0.72) yet not significantly different. The risk of adverse events is not increased except for (avoidable) subcutaneous phototoxicity at the injection site. CONCLUSION: Temoporfin-PDT can safely be delivered to hilar bile duct cancer patients and results in prolonged patency of hilar bile ducts, a trend for longer survival time, and similar palliation as with P-PDT.
UNLABELLED: Photodynamic therapy using porfimer (P-PDT) improves palliation and survival in nonresectable hilar bile duct cancer. Tumoricidal penetration depth of temoporfin-PDT (T-PDT) is twice that of P-PDT. In a single-arm phase II study we investigated the safety, efficacy, survival time, and adverse events of T-PDT compared with previous data on P-PDT. Twenty-nine patients (median 71 [range 47-88] years) with nonresectable hilar bile duct cancer were treated with T-PDT (median 1 [range 1-4] sessions) plus stenting and followed up every 3 months. The PDT was well tolerated. In patients with occluded segments at baseline (n=28) a reopening of a median of 3 (range 1-7) segments could be achieved: n=16 local response and n=11 stable local disease, one progressive disease. Cholestasis and performance significantly improved when impaired at baseline. Time to local tumor progression was a median of 6.5 (2.7-41.0) months. Overall survival time was a median of 15.4 (range 4.4-62.4) months. Patients died from tumor progression (55%), cholangitis (18%), pneumonia (7%), hemobilia (7%), esophagus variceal hemorrhage (3%), and vascular diseases (10%). Adverse events were cholangitis (n=4), liver abscess (n=2), cholecystitis (n=2), phototoxic skin (n=5), and injection site reactions (n=7). Compared to previous P-PDT, T-PDT shows prolonged time to local tumor progression (median 6.5 versus 4.3 months, P<0.01), fewer PDT treatments needed (median 1 versus 3, P<0.01), a higher 6-month survival rate (83% versus 70%, P<0.01), and a trend for longer overall median survival (15.4 versus 9.3 months, P=0.72) yet not significantly different. The risk of adverse events is not increased except for (avoidable) subcutaneous phototoxicity at the injection site. CONCLUSION:Temoporfin-PDT can safely be delivered to hilar bile duct cancerpatients and results in prolonged patency of hilar bile ducts, a trend for longer survival time, and similar palliation as with P-PDT.
Authors: Pim B Olthof; Robert J Coelen; Michal Heger; Heinz-Josef Klümpen; Erik A Rauws; Thomas M van Gulik Journal: United European Gastroenterol J Date: 2017-01-12 Impact factor: 4.623
Authors: Merel S Koedijk; Ben J M Heijmen; Bas Groot Koerkamp; Ferry A L M Eskens; Dave Sprengers; Jan-Werner Poley; Dik C van Gent; Luc J W van der Laan; Bronno van der Holt; François E J A Willemssen; Alejandra Méndez Romero Journal: BMJ Open Date: 2018-10-15 Impact factor: 2.692
Authors: Caixia Yue; Chunlei Zhang; Gabriel Alfranca; Yao Yang; Xinquan Jiang; Yuming Yang; Fei Pan; Jesús M de la Fuente; Daxiang Cui Journal: Theranostics Date: 2016-02-05 Impact factor: 11.556
Authors: Andrej Wagner; Marcus Wiedmann; Andrea Tannapfel; Christian Mayr; Tobias Kiesslich; Gernot W Wolkersdörfer; Frieder Berr; Johann Hauss; Helmut Witzigmann Journal: Int J Mol Sci Date: 2015-11-06 Impact factor: 5.923
Authors: Christian Mayr; Marlena Beyreis; Andrej Wagner; Martin Pichler; Daniel Neureiter; Tobias Kiesslich Journal: Biomed Res Int Date: 2016-11-09 Impact factor: 3.411
Authors: Robert J S Coelen; Jantien A Vogel; Laurien G P H Vroomen; Eva Roos; Olivier R C Busch; Otto M van Delden; Foke van Delft; Michal Heger; Jeanin E van Hooft; Geert Kazemier; Heinz-Josef Klümpen; Krijn P van Lienden; Erik A J Rauws; Hester J Scheffer; Henk M Verheul; Jan de Vries; Johanna W Wilmink; Barbara M Zonderhuis; Marc G Besselink; Thomas M van Gulik; Martijn R Meijerink Journal: BMJ Open Date: 2017-09-01 Impact factor: 2.692